definiens: means, subject to Section 4.9, collectively:(a ) ( i ) all Collaboration Candidates that during the Research Program Term are classified as TerminatedCompounds by the JRC, ( ii ) all Fully Screened Collaboration Candidates that as of the end of the ResearchProgram Term are not determined by the JRC or [COMPANY] to be Active+ Compounds, and ( iii ) eachUnscreened Collaboration Candidate that, as of the later of the end of the Research Program Term and the [ * * * * * * * * ] after the date that [COMPANY] has received all screening data and analyses generated in the ResearchProgram for such Unscreened Collaboration Candidate, is not selected by [COMPANY] for additional researchactivities pursuant to Section 4.8;(b ) all ( i ) Collaboration Candidates that, during the Research Program Tail Period, are classified asTerminated Compounds by the JRC, and ( ii ) Fully Screened Collaboration Candidates that within [ * * * * * * * * ] afterthe applicable meeting of the JRC ( A ) are not determined by the JRC or [COMPANY] to be Active+ Compoundsand ( B ) are not selected by [COMPANY] for additional research activities pursuant to Section 4.8 during theremainder of the Tail Period;(c ) all Active+ Compounds and other Collaboration Candidates that, as of the end of the Research ProgramTail Period, are not ( i ) designated as Lead Collaboration 58Compounds ( and are not Related Collaboration Compounds with respect to a Lead Collaboration Compound),(ii ) the subject of an Additional Research Program that continues after the Research Program Tail Period duringthe remainder of the Tail Period, or ( iii ) selected by [COMPANY] prior to the end of the Research Program TailPeriod ( or, in the case of a Collaboration Candidate that becomes a Fully Screened Collaboration Candidate orthat is generated or identified in an Additional Research Program after the end of the Research Program TailPeriod, prior to the end of the Tail Period ) for additional research activities pursuant to Section 4.8 during theremainder of the Tail Period;(d ) all Active+ Compounds and other Collaboration Candidates that are not designated as Lead CollaborationCompounds ( and are not Related Collaboration Compounds with respect to a Lead Collaboration Compound ) as ofthe end of the Tail Period ( or, if later, the resolution of any dispute pursuant to Section 4.3.2 or as provided inSection 4.9);(e ) all Lead Collaboration Compounds that are replaced in the Collaboration Compound Pool pursuant toSection 4.7.1 after the end of the Research Program Tail Period, unless any such replaced Lead CollaborationCompound ( or any Related Collaboration Compound with respect thereto ) is a Related Collaboration Compoundwith respect to another Lead Collaboration Compound, in which case such compound shall be or remain aRelated Collaboration Compound;(f ) all Option Compounds that become Terminated Compounds pursuant to Section 5.10.2;(g ) each Excluded Derivative as of the date it is determined to be an Excluded Derivative ; and(h ) all other compounds or products expressly identified as a Terminated Compound pursuant toSection 2.2.4(l ), 2.2.4(n ), 3.3.2(b)(2 ), 4.3.2, 11.2.2(a ), 11.3.1(a ), 11.3.1(g ), 11.3.2(a ) and 11.3.3(a ) of thisAgreement;including in each case ( ( a ) through ( h ) ), any salt form, polymorph, crystalline form, hydrate, solvate or formulationthereof